KMUH (N-κ-maleimidoundecanoic acid hydrazide) - Citations

KMUH (N-κ-maleimidoundecanoic acid hydrazide) - Citations

View additional product information for KMUH (N-κ-maleimidoundecanoic acid hydrazide) - Citations (22111)

Showing 2 product Citations

Citations & References
Abstract
Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
AuthorsYang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ
JournalClin Cancer Res
PubMed ID16778107
The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-positive rat glioma, F98(npEGFRvIII). ... More
Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
AuthorsWu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K
JournalMol Cancer Ther
PubMed ID16432162
We have constructed a drug delivery vehicle that targets the epidermal growth factor receptor (EGFR) and its mutant isoform EGFRvIII. The monoclonal antibody, cetuximab, previously known as C225, which binds to both EGFR and EGFRvIII, was covalently linked via its Fc region to a fifth-generation (G5) polyamidoamine dendrimer containing the ... More